173 results on '"Lenting, Peter J."'
Search Results
2. Mortality, cardiac and cerebral damages reduction by IL-1 inhibition in a murine model of TTP
3. Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc
4. The role of platelets and von Willebrand factor in the procoagulant phenotype of inflammatory bowel disease
5. Shear Forces Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia
6. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab.
7. Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy
8. ANGIOPOIETIN-2 BINDS TO MULTIPLE INTERACTIVE SITES WITHIN VON WILLEBRAND FACTOR
9. IdeS, a new option to optimize the management of patients with hemophilia A on emicizumab
10. Antithrombin-lowering in hemophilia: A closer look at fitusiran
11. VON WILLEBRAND FACTOR: FROM FIGURANT TO MAIN CHARACTER IN THE SCENE OF INFLAMMATION
12. A nanobody against the von Willebrand factor A3-domain detects ADAMTS13-induced proteolysis in congenital & acquired VWD
13. A FVIII-Mimetic Bispecific Antibody with an Embedded Self-Regulation Mechanism Reduces the Risk of Prothrombotic Events for the Treatment of Haemophilia a
14. Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort
15. Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S
16. Towards novel treatment options in von Willebrand disease
17. Identification of von Willebrand factor D4 domain mutations in patients of Afro‐Caribbean descent: In vitro characterization
18. Osteoprotegerin modulates platelet adhesion to von Willebrand factor during release from endothelial cells
19. TaSER: Combining forces to stop the clot
20. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis
21. A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated von Willebrand disease type 2B patient
22. How to keep the factor VIII/von Willebrand factor complex in the circulation
23. A reactive center loop–based prediction platform to enhance the design of therapeutic SERPINs
24. Non-inhibitory antibodies inducing increased emicizumab clearance in a severe haemophilia A inhibitor patient
25. von Willebrand disease: what does the future hold?
26. Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates
27. The VWF/LRP4/αVβ3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells
28. Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor
29. In vivo modulation of a dominant‐negative variant in mouse models of von Willebrand disease type 2A
30. A compact integrated microfluidic oxygenator with high gas exchange efficiency and compatibility for long-lasting endothelialization
31. Functional and clinical aspects of the anti-hemophilic bispecific antibody emicizumab
32. P.31 Von Willebrand Factor Induces Vascular Smooth Muscle Cell Proliferation and Migration Through Low Density Lipoprotein-Related Receptor Protein 4 and αvβ3 Integrin
33. Coagulation markers are independent predictors of increased oxygen requirements and thrombosis in COVID‐19: Response from Original Authors Susen, et al.
34. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID‐19
35. Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications
36. Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation
37. Author Correction: Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
38. Monoclonal gammopathy of clinical significance: in vivo demonstration of the anti-thrombotic effect of an acquired anti-thrombin antibody
39. A hemophilia A mouse model for the in vivo assessment of emicizumab function
40. Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
41. Laboratory monitoring of hemophilia A treatments: new challenges
42. Single‐domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors
43. A single‐domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor
44. Cofactor and Cofactor Mimetics
45. A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A
46. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia
47. Emicizumab and thrombosis: The story so far
48. Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA
49. von Willebrand Factor and Management of Heart Valve Disease
50. Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.